Director/PDMR Shareholding

e-Therapeutics plc ("e-Therapeutics" or the "Company")

2 October 2012

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

The Company received notification on 1 October that, on 28 September, Novotech Investment Limited (NIL), a company of which Professor Malcolm Young (CEO) is a Director and in which he has options to subscribe for ordinary shares, sold 20,000 ordinary shares in e-Therapeutics plc at £0.37 per share. Professor Malcolm Young is one of three directors in NIL and as such had no ability by himself to prevent NIL from selling the 20,000 shares. It is understood that NIL has disposed of the shares to enable NIL to discharge its obligations to third parties. 

Following the sale, Professor Young's direct beneficial interest remains unchanged at 20,620,482 shares, representing 14.92% of the total issued share capital of the Company (of which 10,310,241 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife). However, Professor Young's indirect holding relating to interests that he holds in NIL and Novotech Syndicate LLP has been reduced by 5,968 shares, and now stands at 422,544 shares, representing 0.31% of the total issued share capital of the Company.

Contacts

e-Therapeutics plc

Daniel Elger

Tel: +44 (0)79 0991 5068

www.etherapeutics.co.uk

Panmure Gordon (UK) Limited

Fred Walsh / Hannah Woodley / Grishma Patel

Tel: +44 (0) 20 7886 2500

www.panmure.com